These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 15134553)

  • 1. HIV protease inhibition: limited recent progress and advances in understanding current pitfalls.
    Rodríguez-Barrios F; Gago F
    Curr Top Med Chem; 2004; 4(9):991-1007. PubMed ID: 15134553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV-1 protease inhibitors: a comparative QSAR analysis.
    Kurup A; Mekapati SB; Garg R; Hansch C
    Curr Med Chem; 2003 Sep; 10(17):1679-88. PubMed ID: 12871116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protein promiscuity: drug resistance and native functions--HIV-1 case.
    Fernández A; Tawfik DS; Berkhout B; Sanders R; Kloczkowski A; Sen T; Jernigan B
    J Biomol Struct Dyn; 2005 Jun; 22(6):615-24. PubMed ID: 15842167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir.
    Lefebvre E; Schiffer CA
    AIDS Rev; 2008; 10(3):131-42. PubMed ID: 18820715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV/AIDS.
    Ghosh AK; Osswald HL; Prato G
    J Med Chem; 2016 Jun; 59(11):5172-208. PubMed ID: 26799988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and evaluation of A-seco type triterpenoids for anti-HIV-1protease activity.
    Wei Y; Ma CM; Hattori M
    Eur J Med Chem; 2009 Oct; 44(10):4112-20. PubMed ID: 19493591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting dynamic pockets of HIV-1 protease by structure-based computational screening for allosteric inhibitors.
    Kunze J; Todoroff N; Schneider P; Rodrigues T; Geppert T; Reisen F; Schreuder H; Saas J; Hessler G; Baringhaus KH; Schneider G
    J Chem Inf Model; 2014 Mar; 54(3):987-91. PubMed ID: 24528206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protease Inhibitors for the Treatment of HIV/AIDS: Recent Advances and Future Challenges.
    Voshavar C
    Curr Top Med Chem; 2019; 19(18):1571-1598. PubMed ID: 31237209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent developments of peptidomimetic HIV-1 protease inhibitors.
    Qiu X; Liu ZP
    Curr Med Chem; 2011; 18(29):4513-37. PubMed ID: 21864279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Using Hierarchical Virtual Screening To Combat Drug Resistance of the HIV-1 Protease.
    Li N; Ainsworth RI; Ding B; Hou T; Wang W
    J Chem Inf Model; 2015 Jul; 55(7):1400-12. PubMed ID: 25993532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Action of anti-HIV drugs and resistance: reverse transcriptase inhibitors and protease inhibitors.
    Imamichi T
    Curr Pharm Des; 2004; 10(32):4039-53. PubMed ID: 15579086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and biological evaluation of novel HIV-1 protease inhibitors using tertiary amine as P2-ligands.
    Yang ZH; Bai XG; Zhou L; Wang JX; Liu HT; Wang YC
    Bioorg Med Chem Lett; 2015 May; 25(9):1880-3. PubMed ID: 25838144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Advances in novel anti-HIV-1 drugs and drug candidates: 2005-2008].
    Zheng PR; Xue H; Xiao ZY; Liu G
    Yao Xue Xue Bao; 2010 Feb; 45(2):154-64. PubMed ID: 21351426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Defining HIV-1 protease substrate selectivity.
    Beck ZQ; Morris GM; Elder JH
    Curr Drug Targets Infect Disord; 2002 Mar; 2(1):37-50. PubMed ID: 12462152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peptide inhibitors of HIV-1 and HIV-2 proteases: a comparative study.
    Pichová I; Weber J; Litera J; Konvalinka J; Vondrásek J; Soucek M; Strop P; Majer P; Heuser AM; Kraeusslich HG
    Leukemia; 1997 Apr; 11 Suppl 3():120-2. PubMed ID: 9209317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of protease inhibitors and the fight with drug-resistant HIV-1 variants.
    Mitsuya H; Maeda K; Das D; Ghosh AK
    Adv Pharmacol; 2008; 56():169-97. PubMed ID: 18086412
    [No Abstract]   [Full Text] [Related]  

  • 17. Highly active antiretroviral therapy failure and protease and reverse transcriptase human immunodeficiency virus type 1 gene mutations.
    Monno L; Appice A; Cavaliere R; Scarabaggio T; Angarano G
    J Infect Dis; 1999 Aug; 180(2):568-71. PubMed ID: 10395885
    [No Abstract]   [Full Text] [Related]  

  • 18. New active HIV-1 protease inhibitors derived from 3-hexanol: conformation study of the free inhibitors in crystalline state and in complex with the enzyme.
    Ziółkowska NE; Bujacz A; Randad RS; Erickson JW; Skálová T; Hašek J; Bujacz G
    Chem Biol Drug Des; 2012 May; 79(5):798-809. PubMed ID: 22296826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti HIV-1 agents 6. Synthesis and anti-HIV-1 activity of indolyl glyoxamides.
    Wang Y; Huang N; Yu X; Yang LM; Zhi XY; Zheng YT; Xu H
    Med Chem; 2012 Sep; 8(5):831-3. PubMed ID: 22741604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validated predictive QSAR modeling of N-aryl-oxazolidinone-5-carboxamides for anti-HIV protease activity.
    Halder AK; Jha T
    Bioorg Med Chem Lett; 2010 Oct; 20(20):6082-7. PubMed ID: 20832304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.